The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
MEX:PACB's 9-Day RSI is ranked worse than 81.36% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 52.28
vs MEX:PACB: 27.38
Pacific Biosciences of California (MEX:PACB) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Pacific Biosciences of California 9-Day RSI Related Terms
MEX:PACB vs KIDS, MOBI, SI: 9-Day RSI Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's 9-Day RSI falls into.
Pacific Biosciences of California (MEX:PACB) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (MEX:PACB) has a 9-Day RSI of 27.38 as of Jul. 05, 2026. According to the industry distribution chart, Pacific Biosciences of California ranks #707 out of 869 companies in the Medical Devices & Instruments industry, placing it in the top 81.4%.
Is Pacific Biosciences of California's 9-Day RSI too high?
Pacific Biosciences of California's current 9-Day RSI is 27.38. The Medical Devices & Instruments industry median 9-Day RSI is 52.28. Pacific Biosciences of California's value of 27.38 is 47.6% below this industry median. Based on the distribution chart, Pacific Biosciences of California ranks #707 out of 869 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pacific Biosciences of California has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's 9-Day RSI compare to KIDS and MOBI?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #707 out of 869 companies for 9-Day RSI. This places Pacific Biosciences of California in the lower half of its industry. The industry median 9-Day RSI is 52.28. Pacific Biosciences of California's value of 27.38 is 47.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 52.28, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Biosciences of California's current 9-Day RSI of 27.38 is 47.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 52.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Biosciences of California's current 9-Day RSI is 27.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Pacific Biosciences of California (MEX:PACB) has a current 9-Day RSI of 27.38. The stock's GF Value™ is MXN26.60, compared to a current price of MXN27.50 — trading 3.4% above its estimated fair value. The current 9-Day RSI is 27.38 and 47.6% below the Medical Devices & Instruments industry median of 52.28. Pacific Biosciences of California's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Pacific Biosciences of California (MEX:PACB), the current 9-Day RSI is 27.38 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (MEX:PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued.
The current stock price of MXN27.50 is trading 3.4% above its estimated GF Value™ of MXN26.60.
Key valuation signals for MEX:PACB:
9-Day RSI: 27.38
GF Value™: MXN26.60 vs. price of MXN27.50 (3.4% above fair value)
Industry Position: 47.6% below the Medical Devices & Instruments median (#707 of 869)
No single metric tells the full story. See the MEX:PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
55GF Score
Get the complete analysis for MEX:PACB
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PACB has been successfully added to your 